AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 22 min read$IPSC

Century Therapeutics Advances CNTY-813 Toward Clinical Testing With New EASD Data

Century Therapeutics (IPSC) presented new data for CNTY-813, its iPSC-derived islet therapy for type 1 diabetes, at the EASD meeting. The therapy restored normoglycemia in diabetic mice and maintained glycemic control. The company aims to submit an IND application in Q4 2026 and expects initial clinical data in H2 2027. IPSC stock closed at $1.61, down 5.85%.

Original reporting
rttnews.com
Published Oct 2, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 1:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Century Therapeutics Advances CNTY-813 Toward Clinical Testing With New EASD Data — source image
Source · rttnews.com
Decision brief

The 30-second read

$IPSCBullishMed
01

Why it matters

The conference presentation provides the first public efficacy data, which could drive short‑term price movement and influence investor sentiment ahead of the IND filing.

02

Market read

First disclosure of promising pre‑clinical results for a novel diabetes therapy; likely to affect IPSC's stock and the cell‑therapy sector.

03

What to watch

Potential regulatory hurdles for iPSC‑derived therapies and competition from other cell‑therapy platforms.

Relevance 8/10Novelty 8/10Timing: today (conference presentation)

Background

Century Therapeutics (IPSC) is a Nasdaq‑listed biotech focused on iPSC‑derived cell therapies for diabetes. The company aims to file an IND for CNTY‑813 in Q4 2026.

Company-level read

Ticker impact

$IPSCBullishHigh confidence
Context

Century Therapeutics presented new pre‑clinical data on its iPSC‑derived islet therapy CNTY‑813 at the EASD conference, including efficacy in mouse and rat studies and progress on IND filing.

Expected impact

potential upside as investors price in the promising trial data and upcoming IND submission

Evidence & confidence

The data are the first public disclosure of efficacy and manufacturing consistency, a material catalyst for a micro‑cap biotech.

Market effects

Sector

Strengthens the broader cell‑therapy and diabetes‑treatment sector by showing progress on off‑the‑shelf islet products.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Modest global relevance as the therapy targets a worldwide disease (type‑1 diabetes).

Counterpoint

What could challenge this read

The data are pre‑clinical; success in humans remains uncertain, and the market may have already priced in optimism.

Key entities

  • company
    Century Therapeutics, Inc.

    Biotech developing iPSC‑derived islet replacement therapy for type‑1 diabetes.

  • organization
    European Association for the Study of Diabetes (EASD)

    Venue where the data were presented.

Read at source← All news

Also covered by

2 outlets

Related articles

OCT 2
$IPSCMedAI 8/10

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Centur

SEC EDGAR 8-K2 min
OCT 2
$IPSCMedAI 8/10

Century Therapeutics presents diabetes therapy data at EASD

Century Therapeutics (NASDAQ:IPSC) presented data on CNTY-813, a diabetes therapy, at the EASD meeting. The therapy showed long-term glycemic control in mouse models and successful engraftment in rats. The company plans to submit an IND application in Q4 2026, with clinical data expected in H2 2027, according to the press release.

investing.com2 min
OCT 2
$IPSCMed

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics (NASDAQ: IPSC) presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. Data showed glycemic control in diabetic mice, scalable production, and immune evasion. The company expects to submit an IND application in Q4 2026 and anticipates initial clinical data in 2H 2027.

globenewswire.com3 min
AUG 18
$IPSCHighAI 8/10

Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

mychesco.com3 min
AUG 12
$IPSCMed

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f

SEC EDGAR 8-K5 min